Clinical Update – August 5, 2020
Updates Included (read on to learn more):
- Virus statistics and hot spots
- Rapid decay of COVID-19 antibodies
- Hydroxychloroquine remains ineffective
- Vaccine trials
Virus Statistics and Hot Spots
|Patient Impact of COVID-19 in U.S.
Places with highest daily reported cases per capita
Daily new reported cases per 100,000 residents as of August 5
- Louisiana: 49 cases (+29% in past week)
- Nevada: 37 cases (+5%)
- Texas: 32 (+23%)
- Mississippi: 32 (-25%)
- Alabama: 32 (-5%)
- Florida: 29 (-38%)
Rapid Decay of COVID-19 Antibodies
- A New England Journal article indicates that re-infection may be possible, especially with those who had mild cases.
- The study found an antibody half-life of approximately 36 days over the observation period.
- Results call for caution regarding antibody-based “immunity passports,” herd immunity, and perhaps vaccine durability, especially in light of short-lived immunity against common human coronaviruses.
- More research is needed.
Hydroxychloroquine Remains Ineffective
- Due to frequent discussion of hydroxychloroquine online and in the media, many doctors have received questions about the efficacy of the drug.
- A study concluded on July 23 found that among patients hospitalized with mild-to-moderate COVID-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.
- This article suggests some strategies for combatting misinformation and addressing false claims from patients.
Click here for information about COVID-19 vaccine trials.